Myriad Genetics, Inc.MYGNNASDAQ
Loading
Operating Cash Flow Growth Under PressureDecelerating
Percentile Rank41
Studio
Year-over-Year Change

Year-over-year operating cash flow growth rate

Percentile
P41
Within normal range
vs 5Y Ago
-0.6x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
PeriodValue
Q4 2025-49.76%
Q3 2025255.15%
Q2 202516.56%
Q1 2025-346.97%
Q4 2024842.86%
Q3 2024-73.08%
Q2 2024113.98%
Q1 202466.00%
Q4 2023-147.51%
Q3 2023-2355.56%
Q2 202397.29%
Q1 2023-331.17%
Q4 2022-175.00%
Q3 202294.37%
Q2 2022-6.88%
Q1 2022-369.70%
Q4 202174.81%
Q3 2021-793.18%
Q2 2021-106.13%
Q1 2021624.09%
Q4 202076.90%
Q3 2020-297.67%
Q2 202078.57%
Q1 2020984.21%
Q4 2019-112.03%
Q3 2019-49.84%
Q2 2019377.27%
Q1 2019-82.54%
Q4 2018384.62%
Q3 2018-83.72%
Q2 2018316.52%
Q1 2018-65.15%
Q4 201740.43%
Q3 2017-35.79%
Q2 2017-10.95%
Q1 201730.89%
Q4 20161182.76%
Q3 2016-105.14%
Q2 201622.88%
Q1 2016-11.90%